avelumab
Trade Name:Bavencio™
Appearance:solution
mixed into larger bags of fluids
Monograph Name:avelumab
Monograph Body:
Avelumab is a fully human monoclonal antibody (IgG1) that inhibits the suppressive effects of PD-L1 on cytotoxic T cells, thereby restoring the anti-tumour immune response.
Time to reach steady state | 4 to 6 weeks (2 to 3 cycles) when administered every 2 weeks |
Avelumab is distributed mainly in the systemic circulation, with less distribution to the extracellular space.
Avelumab exposure increases proportionally to dose in the range of 10-20 mg/kg every 2 weeks.
Monoclonal antibodies are degraded into small peptides and amino acids via catabolic pathways.
Half-life |
6.1 days (terminal) |
- Merkel cell carcinoma (MCC)
- Urothelial carcinoma (UC)
Refer to the product monograph for a full list and details of approved indications.
Emetogenic Potential:
Extravasation Potential: None
The following table lists adverse effects that occurred in ≥ 1% of patients in an unresectable locally advanced or metastatic urothelial carcinoma (UC) study, where higher incidences were observed in the avelumab arm. Adverse effects marked with “†” were reported in previously untreated Merkel cell carcinoma. It also includes severe, life-threatening and post-marketing adverse effects from other indications.
ORGAN SITE | SIDE EFFECT* (%) | ONSET** | |||
---|---|---|---|---|---|
Cardiovascular | Hypertension (10%) † | E | |||
Hypotension (2%) | E | ||||
Myocarditis (rare) | E D | ||||
Dermatological | Erythema multiforme (rare) | E | |||
Rash, pruritus (20%) (1% severe) | E | ||||
Gastrointestinal | Abdominal pain (13%) † | E | |||
Anorexia, weight loss (14%) | E | ||||
Constipation (16%) | E | ||||
Diarrhea (17%) (may be severe, 2% colitis) | E D | ||||
Nausea, vomiting (16%) | E | ||||
General | Edema (13%) † | E | |||
Fatigue (36%) | E | ||||
Fever, chills (15%) | I | ||||
Sarcoidosis (rare) - disease flare | E | ||||
Hematological | Anemia (16%) † | E D | |||
Hepatobiliary | ↑ LFTs (5%) (2% severe; 1% autoimmune hepatitis) | E D | |||
Pancreatitis (rare, in combination with axitinib) | E | ||||
Hypersensitivity | Hypersensitivity (2%) | I E | |||
Infusion related reaction (10%) (may be severe) | I | ||||
Immune | Antibody response (4%) | E D | |||
Metabolic / Endocrine | Adrenal insufficiency (2%) | E D | |||
Hyperglycemia (4%) ; diabetes mellitus (type 1; rare) | E D | ||||
Hyperthyroidism (6%) | E D | ||||
Hypothyroidism (12%) | E D | ||||
Musculoskeletal | Musculoskeletal pain (24%) | E | |||
Other - Rheumatoid arthritis (rare) | E | ||||
Nervous System | Guillain-Barre syndrome (rare) | E | |||
Myasthenia gravis (rare) | E | ||||
Myositis (<1%) | E D | ||||
Ophthalmic | Uveitis (rare) | E | |||
Renal | Nephrotoxicity (2%) (nephritis - rare) | E D | |||
Respiratory | Cough, dyspnea (14%) | E | |||
Pneumonitis (3%) | E D | ||||
Urinary | Urinary tract infection (20%) | E |
* "Incidence" may refer to an absolute value or the higher value from a reported range.
"Rare"
may refer to events with < 1% incidence, reported in post-marketing, phase 1 studies,
isolated data or anecdotal
reports.
** I = immediate (onset in hours to days)
E = early (days to weeks)
D = delayed (weeks to months)
L = late (months to years)
The most common side effects for avelumab include fatigue, musculoskeletal pain, rash/pruritus, diarrhea, anemia, constipation, nausea/vomiting, fever, chills, anorexia/weight loss, cough/dyspnea.
Refer to CCO's Immune Checkpoint Inhibitor Toxicity Management Guideline for detailed descriptions of Immune-related toxicities and their management.
Presentation of immune-mediated reactions may be different compared to other anti-cancer agents and early diagnosis and appropriate management is critical.
Immune-mediated reactions such as rash, pneumonitis, colitis, hepatitis, nephritis, endocrinopathies and neuropathies were reported in patients who received avelumab and may be severe or fatal.
Anti-drug antibodies have been reported, but did not appear to impact the risk of infusion-related reactions.
Refer to protocol by which patient is being treated.
Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the hepatitis B virus screening and management guideline.
Avoid the use of corticosteroids or immunosuppressants before starting treatment.
Premedication with an antihistamine and acetaminophen prior to the first 4 infusions is recommended. Consider for subsequent infusions based on clinical judgement and prior infusion reactions.
Avelumab 10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity
Healthcare professionals should also consult the most recent avelumab product monograph for additional information.
Dose reductions are not recommended for avelumab . Doses may be delayed or discontinued based on toxicity.
Summary of Principles of Management of Immune-Related Adverse Effects (irAEs):
-
Immune-related adverse effects (irAEs) are different in their presentation, onset and duration compared to conventional chemotherapy. Patient and provider education is essential.
-
Initial irAEs presentation can occur months after completion of treatment and affect multiple organs.
-
Dose escalation or reduction is not recommended.
-
If no other cause can be identified (such as infection), any new symptom should be considered immune-related and prompt treatment initiated.
-
Organ-specific system-based toxicity management is recommended.
Refer to CCO's Immune Checkpoint Inhibitor Toxicity Management Guideline for detailed descriptions of Immune-related toxicities and their management.
Infusion-related reactions:
Toxicity Grade | Action |
1 | Slow infusion rate by 50% |
2 | Interrupt infusion until ≤ grade 1; restart at 50% lower infusion rate. |
≥3 | Discontinue |
Refer to CCO's Immune Checkpoint Inhibitor Toxicity Management Guideline for detailed descriptions for immune-related hepatic toxicity management.
Hepatic impairment | Avelumab dose |
Mild (bilirubin ≤ ULN and AST > ULN OR bilirubin 1-1.5 x ULN) | no change |
Moderate (bilirubin 1.5-3 x ULN) | |
Severe (bilirubin > 3 x ULN) | no data |
Refer to CCO's Immune Checkpoint Inhibitor Toxicity Management Guideline for detailed descriptions for immune-related renal toxicity management.
Creatinine clearance (ml/min) | Avelumab dose |
≥ 60 | no change |
30-59 | |
15-29 |
Metastatic Merkel Cell Carcinoma:
Differences in safety or efficacy between patients aged 65 and older compared to younger patients have not been evaluated
Locally Advanced or Metastatic Urothelial Carcinoma:
No overall differences in safety or efficacy were reported between elderly patients and younger patients. There is limited safety data in patients ≥ 75 years of age in maintenance treatment after first-line platinum-based chemotherapy.
Safety and efficacy in pediatric patients have not been established.
-
DO NOT administer as an IV push or bolus.
-
Dilute avelumab with 0.9% or 0.45% saline solution (preferably 250 mL) prior to infusion. It must not be mixed with other products or diluents.
-
Mix the diluted solution by gentle inversion; do not shake.
-
Infuse over 60 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 micrometer in-line or add-on filter.
-
Do not co-administer with other drugs through the same IV line; flush the line with 0.9% or 0.45% saline after administration.
- Avelumab is compatible with polyethylene, polypropylene and ethylene vinyl acetate infusion bags, glass bottles, polyvinyl chloride infusion sets and in-line filters with polyethersulfone membranes and pore sizes of 0.2 micrometer.
-
Avelumab vials should be stored at 2-8oC; do not freeze.
-
Store in the original container and protect from light.
- Patients who have a hypersensitivity to this drug or any components of the formulation.
-
Patients with pre-existing autoimmune disease (AID) were excluded from clinical trials. Data from post-marketing suggest that there are risks of immune-related reactions in patients with pre-existing AID. Consider the risks versus the benefit of giving avelumab in these patients.
-
Use with caution and monitor closely in patients with pre-existing conditions such as colitis, hepatic impairment, respiratory or endocrine disorders, such as hypo or hyperthyroidism or diabetes mellitus.
-
Avelumab may cause fatigue; patients should be advised not to drive or operate machinery/tools until they are sure of feeling well.
Other Drug Properties:
-
Carcinogenicity:
Unknown
-
Crosses placental barrier:
Yes
-
Fetotoxicity:
Likely
Avelumab may cause fetal harm and is not recommended for use in pregnancy. Adequate contraception should be used by patients and their partners during treatment, and for at least 1 month after the last dose.
-
Excretion into breast milk:
Likely
Breastfeeding is not recommended during treatment and for at least 1 month after the last dose.
-
Fertility effects:
Unknown
No formal pharmacokinetic drug-drug interaction studies have been conducted. Avelumab is mainly metabolized through catabolic pathways; it is not expected that avelumab will have drug-drug interactions with other medications.
Use of systemic corticosteroids or immunosuppressants should be avoided prior to starting avelumab because of the potential for interference with avelumab's efficacy. They can be used to treat immune-mediated reactions after starting the drug.
Acetaminophen may affect the response to immune checkpoint inhibitors. Further clinical studies are needed to determine the exact mechanism and the appropriate clinical management (Bessede et al, 2022).
Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.
Refer to the hepatitis B virus screening and management guideline for monitoring during and after treatment.
Monitor Type | Monitor Frequency |
---|---|
CBC |
Baseline, before each dose and as clinically indicated |
Liver function tests |
Baseline, before each dose and as clinically indicated; frequent with severe toxicity |
Renal function tests |
Baseline, periodically during treatment and as clinically indicated; frequent with severe toxicity |
Thyroid function tests |
Baseline and before each dose, or at least once monthly |
Blood glucose |
Baseline, periodically during treatment and as clinically indicated |
Clinical toxicity assessment for infusion-related reactions, fatigue, immune-mediated reactions, including GI, skin, respiratory, neurologic, cardiac, ophthalmic and endocrine toxicities |
At each visit and as clinically indicated |
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
New Drug Funding Program (NDFP Website )
- Avelumab - Metastatic Merkel Cell Carcinoma
- Avelumab - Maintenance Treatment for Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Bessede A, Marabelle A, Guegan JP, et al. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol 2022;33(9):909-15.
D'Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer 2021 Jul;9(7):e002646.
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-1385.
Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51–64.
Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med . 2020 Sep 24;383(13):1218-30.
Product monograph: Avelumab (Bavencio®), EMD Serono, August 6, 2024.
January 2025 Updated Adverse effects and Warnings sections
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.
Bessede A, Marabelle A, Guegan JP, et al. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol 2022;33(9):909-15.
D'Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer 2021 Jul;9(7):e002646.
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-1385.
Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51–64.
Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med . 2020 Sep 24;383(13):1218-30.
Product monograph: Avelumab (Bavencio®), EMD Serono, August 6, 2024.
avelumab (patient)
Info Sheet Introduction:- For treating certain types of skin and bladder or urinary tract cancers.
- Avelumab is an immunotherapy medication. For more information on immunotherapy medications, click here.
Other Name: Bavencio®
mixed into larger bags of fluids
For treating certain types of skin and bladder or urinary tract cancers.
Avelumab is an immunotherapy medication. For more information on immunotherapy medications, click here.
Tell your health care team if you have or had significant medical condition(s), such a
an organ transplant
immune conditions (such as ulcerative colitis, Crohn's, rheumatoid arthritis or lupus)
problems with your hormone producing glands (such as the thyroid or adrenal glands)
diabetes
liver, heart, kidney or lung problems
active infections or
any allergies
Remember to:
- Tell your health care team about all of the other medications you are taking.
- Keep taking other medications that have been prescribed for you, unless you have been told not to by your health care team.
Talk to your health care team about:
- How this medication may affect your sexual health.
- How this medication may affect your ability to have a baby, if this applies to you.
This medication may harm an unborn baby. Tell your health care team if you or your partner are pregnant, become pregnant during treatment, or are breastfeeding.
- If there is any chance of pregnancy happening, you and your partner together must use 2 effective forms of birth control at the same time until at least 1 month after your last dose. Talk to your health care team about which birth control options are best for you.
- Do not breastfeed while on this medication and for at least 1 month after the last dose.
This drug is given through an IV (injected into a vein), usually every 2 weeks. Talk to your health care team about your treatment schedule.
You may be given this treatment along with other medication(s) to help prevent a reaction.
If you miss your treatment appointment, talk to your health care team to find out what to do.
To Prevent Allergic Reaction
You will be given medications before your first 4 treatments to help prevent allergic reactions before they start. Your health care team will let you know if you need these medications after your first 4 treatments.
There are different types of medications to stop allergic reactions. They are called:
- antihistamines (such as diphenhydramine or Benadryl®)
- analgesics/antipyretics (such as acetaminophen or Tylenol®)
Will this medication interact with other medications or natural health products?
Although this medication is unlikely to interact with other medications, vitamins, foods and natural health products, tell your health care team about all of your:
prescription and over-the-counter (non-prescription) medications and all other drugs, such as cannabis/marijuana (medical or recreational)
natural health products such as vitamins, herbal teas, homeopathic medicines, and other supplements
Check with your health care team before starting or stopping any of them.
What should I do if I feel unwell, have pain, a headache or a fever?
Always check your temperature to see if you have a fever before taking any medications for fever or pain (such as acetaminophen (Tylenol®) or ibuprofen (Advil®)).
Fever can be a sign of infection that may need treatment right away.
If you take these medications before you check for fever, they may lower your temperature and you may not know you have an infection.
How to check for fever:
Keep a digital (electronic) thermometer at home and take your temperature if you feel hot or unwell (for example, chills, headache, mild pain).
- You have a fever if your temperature taken in your mouth (oral temperature) is:
- 38.3°C (100.9°F) or higher at any time
OR
- 38.0°C (100.4°F) or higher for at least one hour.
- 38.3°C (100.9°F) or higher at any time
If you do have a fever:- Try to contact your health care team. If you are not able to talk to them for advice, you MUST get emergency medical help right away.
- Ask your health care team for the Fever pamphlet for more information.
If you do not have a fever but have mild symptoms such as headache or mild pain:
Ask your health care team about the right medication for you. Acetaminophen (Tylenol®) is a safe choice for most people.
Talk to your health care team before you start taking Ibuprofen (Advil®, Motrin®), naproxen (Aleve®) or ASA (Aspirin®), as they may increase your chance of bleeding or interact with your cancer treatment.
Talk to your health care team if you already take low dose aspirin for a medical condition (such as a heart problem). It may still be safe to take.
What to DO while on this medication:
DO check with your health care team before getting any vaccinations, surgery, dental work or other medical procedures.
DO consider asking someone to drive you to and from the hospital on your treatment days especially for your first 4 treatments. You may feel drowsy or dizzy after your treatment.
DO tell your healthcare team about ANY new symptom you may develop. You may need urgent medical treatment.
What NOT to DO while on this medication:
DO NOT smoke or drink alcohol while on treatment without talking to your health care team first. Smoking and drinking can make side effects worse and make your treatment not work as well.
DO NOT drive, operate machinery or do any tasks that need you to be alert if you feel tired.
The following table lists side effects that you may have when getting avelumab. The table is set up to list the most common side effects first and the least common last. It is unlikely that you will have all of the side effects listed and you may have some that are not listed.
- Avelumab makes your immune system work harder. Your immune system is what fights infections and your cancer.
- When your immune system is working harder, you may have side effects in your bowels, liver, lungs, skin, and other organs. You may also have changes in hormone levels in your body.
- These side effects may be mild or may become serious or life-threatening in rare cases.
- They may happen during your treatment or weeks to months after your treatment ends.
- Some things to watch for are:
- diarrhea
- a new cough
- problems with breathing
- rash
- any other new symptom
- If you have side effects, you must talk to your health care team right away. You may need urgent treatment.
Read over the side effect table so that you know what to look for and when to get help. Refer to this table if you experience any side effects while on avelumab.
Common Side Effects (25 to 49 out of 100 people) | |
Side effects and what to do | When to contact health care team |
Fatigue What to look for?
What to do?
Ask your health care team for the Fatigue pamphlet for more information. | Talk to your health care team if it does not improve or if it is severe |
Less Common Side Effects (10 to 24 out of 100 people) | |
Side effects and what to do | When to contact health care team |
Mild joint, muscle pain or cramps What to look for?
What to do?
Ask your health care team for the Pain pamphlet for more information. | Talk to your health care team if it does not improve or if it is severe |
Rash; itchiness What to look for?
What to do? To prevent and treat dry skin:
If this happens, talk to your health care team or go to the emergency room right away. Talk to your health care team. If you are unable to talk to the team for advice, you must get emergency medical help right away. | Talk to your health care team for advice
Talk to your health care team. If you are unable to talk to the team for advice, you must get emergency medical help right away. |
Diarrhea What to look for?
What to do? If you have diarrhea:
In rare cases, your diarrhea may be severe due to inflammation of the intestines if:
Talk to your health care team. If you are unable to talk to the team for advice, you must get emergency medical help right away. | Talk to your health care team for advice
|
Anemia (low red blood cells) What to look for?
What to do? If your health care team has told you that you have anemia (low red blood cells):
| Talk to your health care team if it does not improve or if it is severe |
Flu-like symptoms You may feel like you have the flu for around 2 days after your IV treatment. These flu-like symptoms may not be signs of an infection. What to look for?
What to do?
| If you do have a fever, try to speak to your health care team. If you are unable to talk to them for advice, you MUST get emergency medical help right away. |
Constipation What to look for?
What to do? To help prevent constipation:
To help treat constipation:
Ask your health care team for the Constipation Pamphlet for more information. | Talk to your health care team if it does not improve or if it is severe |
Nausea and vomiting (Generally mild) What to look for?
What to do? To help prevent nausea:
If you have nausea or vomiting:
| Talk to your healthcare team if nausea lasts more than 48 hours or vomiting lasts more than 24 hours or if it is severe |
Low appetite; weight loss What to look for?
What to do?
Ask your health care team for the Loss of Appetite pamphlet for more information. | Talk to your health care team if it does not improve or if it is severe |
Cough and feeling short of breath What to look for?
What to do?
| Talk to your health care team. If you are not able to talk to your health care team for advice, and you have a fever or severe symptoms, you MUST get emergency medical help right away |
Mild swelling What to look for?
What to do?
If you have swelling:
| Talk to your health care team if it does not improve or if it is severe |
Changes in thyroid activity Thyroid changes may happen weeks to months after you receive your treatment. Your health care team may check your thyroid activity regularly with a blood test. What to look for? Underactive thyroid:
Overactive thyroid (rare):
What to do? Your health care team may give you prescription medication to treat your underactive or overactive thyroid. If you have weight changes along with any of the other symptoms listed, talk to your health care team as soon as possible. | Talk to your health care team as soon as possible |
Allergic reaction (May be severe) What to look for?
| Get emergency medical help right away for severe symptoms |
High blood pressure What to look for?
What to do?
If you have a severe headache get emergency help right away as it may be a sign your blood pressure is too high. | Talk to your health care team if it does not improve or if it is severe |
Other rare, but serious side effects are possible and have been described with avelumab or other similar drugs.
If you experience ANY of the following, speak to your cancer health care provider or get emergency medical help right away:
New cough, chest pain, trouble breathing, shortness of breath or coughing up blood
Peeing more than normal and feeling very thirsty
Who do I contact if I have questions or need help?My cancer health care provider is: ______________________________________________ During the day I should contact:________________________________________________ Evenings, weekends and holidays:______________________________________________
|
Other Notes:
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
April 2022 Updated/Revised info sheet
For more links on how to manage your symptoms go to www.cancercareontario.ca/symptoms.
The information set out in the medication information sheets, regimen information sheets, and symptom management information (for patients) contained in the Drug Formulary (the "Formulary") is intended to be used by health professionals and patients for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or side effects of a certain drug, nor should it be used to indicate that use of a particular drug is safe, appropriate or effective for a given condition.
A patient should always consult a healthcare provider if he/she has any questions regarding the information set out in the Formulary. The information in the Formulary is not intended to act as or replace medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.



- Avelumab - Metastatic Merkel Cell Carcinoma
- Avelumab - Maintenance Treatment for Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
a VEL ue mab
Eligibility Form:

Drug Monograph: Updated Adverse effects and Warnings sections